A virus infection induces a strong T cell response. In the case of a virus; a type-1 response: involving Th1 cells and CD8 T cells. These cells are known to make the cytokine interferon-gamma (IFNg). They express activation markers, including PD-1.
When there is a heavy infection, there is a feedback mechanism. The T cells can now express interleukin-10 (IL-10). IL-10 is an inhibitory cytokine, which will dampen the response to try and limit immune-induced pathology/damage.
This is observed in many type-1 infections, as for SARS here above, and for the Malaria-causing parasite plasmodium here; where the IL-10 can also cause loss of the control of the lung microbiota. This loss of control can cause secondary infections. nature.com/articles/s4146…
These secondary infections are well-known for influenza infections, where many do not die of influenza virus only, but of secondary bacterial or fungal infections.
As is also described here: but some will be fooled by reading the title only. What the paper shows in mice is a heavy H5N1 infection; very strong T cell activation, PD-1 is expressed, and yes, the cells express IL-10: they are highly stimulated.
This does not mean the response to influenza itself is per se suppressed: it is a attempt to spare further lung damage and is totally normal. It does come at a cost of slower viral clearance: but that is offset against not damaging your lungs too much! A excellent deal.
Indeed, subsequent infection with a slightly different influenza virus, that shares antigens, shows that the response is robust and protect the mice very well against reinfection.
The reason is that although the response is purposely curtailed to reduce damage, and as a consequence the virus is cleared later, and you make fewer memory T cells. But; you do make good amounts of memory T cells that rapidly expand when needed, and are very good at killing.
So; the immune response is purposely blunted; it means slower viral clearance, less memory T cells, but less lung damage! Subsequent challenge with a very similar virus for which memory T cells are protective, shows also no subsequent negative impact;
And this is what I mean. Scaremongering due to insufficient knowledge and not understanding the basic principles and context. Please be careful out there, don´t get fooled.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
And yes, if our immune system cannot contain a virus, it can disseminate and end up really every where (someone is trying to convince the world this is SARS-CoV-2 specific; can´t remember who....); including the brain:
When you reduce the number of susceptible hosts, the virus will have less chance to spread, jump host species and to adapt to continue its cycle in a new host.
We make influenza vaccines. We just do not used them, but cull millions of birds every year.
There is a counter arguments: vaccines do not prevent infection. The concern is that this could facilitate spread because infection is not noticed without ill and dying birds.
But as for H7N9; that does not seem to hold.
If you do not read a thread, you have no idea about the data or arguments, you did not read the report concerning the move to endemic status in NL, but you are so incredibly biased, you do not care and just want to promote your political agenda:
Not even the correct country! Really! Why comment if you did not even read the thread! How incredibly biased must you be!
Okay, Stefano got the correct country! But the fraud now cuts the Y-axis to try and make a political point 🤦♂️
Yesterday the advice in The Netherlands is that SARS-CoV-2 should now the treated as any infection. Its status has been set as "endemic". The end of a pandemic is always only called in retrospect.
What is this decision based on?
The number of infections has remained stable with a R around 1 (0,86-1,37).
Few tests are taken and positive tests may not be a reliable indicator. Wastewater analysis shows that there have been waves of SARS-CoV-2.
Variants are all Omicron derived, with many subvariants.
The endemic phase can be defined as the phase in which SC2 is constantly present in the population, but where immunity has built up in the entire population, through vaccination or past infection, making the epidemiological pattern reasonably stable and therefore predictable.
Genetic ablation or pharmacological inhibition of mitochondrial pyruvate carrier (MPC) attenuates severe disease following influenza or SARS-CoV-2.
MPC inhibition dampened pulmonary inflammation and promoted lung recovery, while concurrently reducing blood glucose levels.
MPC inhibition enhanced mitochondrial fitness and destabilized HIF-1α, leading to dampened virus-induced inflammatory responses in both murine and human lung macrophages.